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Abstract 18 
Objectives: Vaccination for dengue with the live attenuated tetravalent CYD-TDV vaccine 19 
(Dengvaxia®) is only recommended in individuals who have had prior dengue virus (DENV) 20 
infection. Rapid diagnostic tests (RDT) for past DENV infection would offer a convenient method 21 
for pre-vaccination screening at point-of-care. A systematic review was conducted to evaluate 22 
the performance of current dengue rapid diagnostic tests (RDTs) for determining dengue 23 
serostatus, using IgG antibodies against DENV as a marker of past infection.   24 
Methods: PubMed and EMBASE databases were searched from 2000 to 2018 to identify studies 25 
evaluating dengue RDTs in individuals with known or possible previous DENV infection. Study 26 
quality was evaluated using GRADE and QUADAS-2 criteria. Semi-structured interviews were 27 
also performed with available dengue RDT manufacturers. 28 
Results: The performance of 4 dengue IgG RDTs was determined in 3137 individuals across 10 29 
studies conducted in 13 countries, with serum used in most of the studies. No studies reported 30 
data for determining dengue serostatus, and limited data were available regarding cross-31 
reactivity with other viruses. The majority of studies demonstrated sensitivities and specificities 32 
between 80-100% for dengue IgG detection in samples from secondary infection or 33 
convalescent timepoints after recent infection.  34 
Conclusions:  Although current dengue IgG RDTs have shown reasonable performance 35 
compared to laboratory-based tests in secondary infection, additional research is needed to 36 
determine how RDTs would perform in relevant populations targeted for vaccination.  New 37 
RDTs or modifications to current RDTs are feasible and may optimize the performance of these 38 
tests for use in a pre-vaccination screening approach.  39 
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Introduction 40 
Dengue is a flavivirus infection spread by Aedes aegypti and Aedes albopictus mosquitoes and is 41 
estimated to infect up to 400 million people worldwide each year [1]. Four distinct dengue virus 42 
serotypes (DENV-1 through DENV-4) cause dengue. After infection with one serotype, an 43 
individual develops lifelong immunity to that serotype, but subsequent infection with another 44 
serotype increases the risk of severe dengue due to antibody dependent enhancement of 45 
infection [2]. The annual incidence of DENV infections has increased exponentially over the past 46 
decades, accompanied by continual geographic expansion to new areas [3,4]. International 47 
travelers are also increasingly affected [5-8]. Effective vector control strategies are not 48 
sustainable [3], community-based approaches have had mixed results [9,10], and compliance 49 
with personal protective measures is difficult [11]. Hence, a dengue vaccine would be an 50 
important tool to combat the dengue burden.  51 
 52 
Currently, the only commercially available dengue vaccine is a tetravalent live attenuated 53 
recombinant vaccine, CYD-TDV (Dengvaxia®), that was developed by Sanofi-Pasteur. Licensed in 54 
approximately 20 countries (as of July 2018) for use in individuals between 9 and 45 years of age 55 
in most countries, it is given with a 3-dose schedule six months apart [12]. In late 2017, Sanofi-56 
Pasteur released long-term safety data stratified by serostatus [13]. Serostatus refers to 57 
whether a person has had a previous DENV infection prior to vaccination: a seropositive person 58 
has had at least one past DENV infection, whereas a seronegative person is dengue-naïve [14]. 59 
Follow-up data of trial participants who were seronegative prior to administration of the vaccine 60 
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showed a 1.75-fold increased risk of hospitalizations due to dengue and severe dengue from 61 
year 3 onwards in comparison with unvaccinated seronegative participants. This unanticipated 62 
outcome is thought to be mediated by antibody dependent enhancement of infection, where 63 
non-neutralizing antibodies can facilitate greater viral entry into monocytes through Fc receptor 64 
binding. This can lead to higher viral load, greater immune activation, and increased risk for 65 
severe dengue. In seropositive individuals, the vaccine was efficacious and safe, conferring long-66 
term protection [13]. Consequently, in April 2018, WHO`s Strategic Advisory Group of Experts on 67 
Immunization (SAGE) revised its recommendations to state a “pre-vaccination screening 68 
strategy” would be the preferred option for countries seeking to use Dengvaxia®, a strategy 69 
whereby only dengue-seropositive individuals should be vaccinated [15-17].  70 
 71 
The choice of tests for dengue diagnosis depends on the timing and purpose. For the diagnosis 72 
of acute DENV infection, tests are based on DENV isolation, presence of dengue viral antigens, 73 
detection of viral nucleic acid in blood through techniques such as RT-PCR, IgM seroconversion, 74 
and/or a four-fold or greater rise in IgG antibody titer in paired blood samples collected at least 75 
14 days apart [18].  Dengue virus and antigen detection are the most accurate diagnostic tools 76 
during the first 5 days of illness, as IgG and IgM antibodies are not produced until 5-7 days after 77 
the onset of symptoms in primary infections [19,20]. IgM levels can become undetectable after 78 
3-6 months, while IgG levels often persist over an individual’s lifetime and can be used to 79 
indicate previous DENV infection [19]. Thus, for the detection of past DENV infections, IgG 80 
antibodies to DENV serve as a marker of past DENV infection. Enzyme-linked immunosorbent 81 
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assays (ELISAs) are the most commonly used laboratory-based serology assays to measure DENV 82 
IgG.  However, ELISAs are time-consuming and require significant laboratory infrastructure, 83 
including instrumentation, trained staff, and refrigeration for reagents.  Delays in turnaround 84 
time would hamper vaccination campaigns as patients would likely be lost to follow-up if 85 
required to return several days later for vaccination. The plaque reduction neutralization test 86 
(PRNT), which measures the titer of neutralizing antibodies against DENV infection, has also 87 
been used to evaluate dengue serostatus, but is even more laborious and expensive than ELISAs, 88 
and hence not routinely used [20]. All serological assays can exhibit some degree of cross-89 
reactivity with other flaviviruses such as Zika, Japanese encephalitis and yellow fever [21].  90 
Rapid diagnostic tests could enable quick, simple screening in dengue endemic areas, which are 91 
often resource-limited and do not have the laboratory capacity to perform ELISA or PRNT 92 
testing. RDTs would also provide with results at the point-of-care to ensure safe vaccine 93 
administration. However, the disadvantage of currently available RDTs is that they have not yet 94 
been validated for screening for past DENV infection and may lack sufficient sensitivity and 95 
specificity to ensure effective vaccination strategies. Since RDTs have typically only been 96 
evaluated in the context of acute DENV infection and not for the detection of past infection, a 97 
systematic review was performed to evaluate the sensitivity and specificity of commercially 98 
available RDTs used for detecting IgG antibodies against DENV as a marker of previous DENV 99 
infection.   100 
Methods 101 
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A systematic review was performed according to the Preferring Reporting Items for Systematic 102 
Reviews and Meta-Analyses (PRISMA) [22]. PubMed and EMBASE databases were searched 103 
from January 1, 2000, to May 31, 2018 to identify relevant publications in peer-reviewed 104 
journals as original scientific research. Search terms were based on a PICO (population, 105 
intervention, comparator, and outcome) question format. The population encompassed 106 
individuals with known or possible previous DENV infection. The intervention was use of RDTs 107 
for detection of DENV IgG antibodies, with the comparator being a validated laboratory-based 108 
ELISA or PRNT assay. The primary outcome was previous DENV infection, which was measured 109 
in studies by the sensitivity and specificity for IgG detection. The search was performed using 110 
the following terms: (dengue OR “dengue virus” OR “dengue fever”) AND (“rapid diagnostic 111 
test” OR “rapid test”) AND (IgG OR sensitivity OR specificity OR “commercially available” OR 112 
“prior infection” OR “previous infection” OR “convalescent” OR seropositive OR seropositivity). 113 
 114 
 115 
After all studies were retrieved, two reviewers independently reviewed all potentially relevant 116 
studies in full.  Disagreements between reviewers were resolved with further discussion 117 
between the two primary reviewers. Studies were included if they met the following inclusion 118 
criteria: studies evaluating the performance of RDTs that are able to test for DENV IgG, studies 119 
comparing RDTs to an established laboratory-based reference standard for determining DENV 120 
infection status, and studies involving samples from patients with prior DENV infection. Studies 121 
were excluded if they contained one or more of the following exclusion criteria: studies on the 122 
use of RDTs for diagnosing acute primary infection only, studies on non-commercially available 123 
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assays, studies not including an RDT, studies using a reference standard that has not been 124 
independently validated, or studies only having a clinical diagnosis as a reference standard.  125 
 126 
Studies were summarized outlining the principal components of each cohort. The summary 127 
included the authors, sample size, study location, test characteristics and reference standard. 128 
Study results were extracted and summarized for all included studies.  Impact on test 129 
performance based on variables such as geographic location (if endemic for dengue and other 130 
flaviviruses), travel history, previous vaccination status, DENV serotype, and previous infection 131 
with other flaviviruses, were also considered. Data from all studies were aggregated, and 132 
frequency statistics were run to describe the population tested across all studies. Forest plots 133 
were generated to depict the range of sensitivity and specificity results for the RDTs studied. 134 
The quality of each study was assessed following QUADAS-2 guidelines, and the complete body 135 
of evidence was evaluated using GRADE guidelines [23,24].  136 
 137 
Semi-structured telephone interviews were conducted by the primary author with dengue rapid 138 
test product managers from all available dengue RDT manufacturers with commercially-139 
available tests that had published data. Questions were asked regarding the performance, 140 
regulatory status, regional availability, intended use, and scientific principles regarding their 141 
dengue RDT technology, the availability of data regarding serostatus determination with RDTs, 142 
and the feasibility of updating the RDTs for use in determining dengue serostatus. Information 143 
was evaluated qualitatively, and common answers regarding the current capabilities of dengue 144 
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RDTs and the potential for detection of dengue serostatus that were mentioned by a majority of 145 
manufacturers were identified.  146 
 147 
Results 148 
The initial search identified 81 potential published studies for evaluation. Of these, 70 studies 149 
did not meet the inclusion and exclusion criteria for the systematic review. Twenty-three studies 150 
contained information on the sensitivity and specificity of dengue RDTs compared to 151 
conventional laboratory-based ELISA testing.  However, 13 of these studies were excluded since 152 
they only evaluated RDT performance for acute primary DENV infection and did not provide 153 
data on the performance of the IgG component for known or possible previous infection. After 154 
filtering studies based on all inclusion and exclusion criteria, 10 studies were included in the 155 
final systematic review (Fig 1).  156 
 157 
Fig 1. PRISMA Diagram  158 
 159 
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 160 
 161 
The 10 studies included prospective and retrospective cohort studies [25-34]. Four dengue RDT 162 
brands were represented: SD BIOLINE Dengue Duo (Alere/Abbott), Panbio Dengue Duo 163 
(Alere/Abbott), OneStep Dengue Fever IgG/IgM RapiCard InstaTest (Cortez), and the GenBody 164 
Dengue IgG/IgM test. Table 1 shows a summary of all studies, including information on the 165 
types of samples tested and patient characteristics.  166 
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Table 1. Study Summary 167 
Author, year, 
country 
Test(s) 
Evaluated 
Sample 
Size 
Sample Type Patient 
Characteristics 
Reference  
Method 
IgG Sensitivity 
(95% CI) 
IgG Specificity 
(95% CI) 
Vickers  
2017  
Jamaica 
OneStep 
Dengue Fever 
IgG/IgM 
RapiCard 
InstaTest 
339 Retrospective 
Serum 
Suspected 
dengue;  
all ages 
ELISA All Samples:  
44.4%  
(38.2-50.7%) 
All Samples:  
95.1% 
(88.0-98.7%) 
Piedrahita  
2016 
Colombia 
SD BIOLINE 
Dengue Duo 
41 Prospective 
Serum 
Suspected 
dengue; ages 
<18 years 
ELISPOT-
MNT 
All Samples:  
26.9%  
(7.9-41%) 
All Samples:  
66.7% 
(39.5-93.9%) 
Vickers 
2015 
Jamaica 
SD BIOLINE 
Dengue Duo 
339 Retrospective 
Serum 
Suspected 
dengue; 
Secondary 
infection: 
ELISA All Samples:  
39.1%  
(33.3-45.2%) 
Secondary 
All Samples:  
N/A 
 
Secondary 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 11
IgM/IgG  
ratio <1.2;  
all ages 
Infection: 
52.1% 
(42-62%) 
Infection: 
100% 
(95.6-100%) 
Krishnanant-
hasivam 
2015 
Sri Lanka 
SD BIOLINE 
Dengue Duo 
143 Prospective 
Plasma 
Suspected 
dengue  
ELISA All Samples: 
38.8% 
(30.1-48.1%) 
All Samples:  
95.5% 
(77.1-99.2%) 
Lee 
2015 
Malaysia 
GenBody 
Dengue 
IgG/IgM, SD 
BIOLINE 
Dengue Duo, 
Panbio Dengue 
Duo 
311 Prospective 
Whole Blood 
Known dengue 
IgG positive 
and negative 
samples 
ELISA IgG-positive 
Samples 
Genbody: 96.7% 
SD BIOLINE: 82% 
Panbio: 
75.3% 
IgG-negative 
Samples 
Genbody: 100% 
SD BIOLINE: 100% 
Panbio: 
100% 
Pal SD BIOLINE 834 Prospective Suspected IgG Capture Convalescent Convalescent 
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2015 
Peru, USA, 
Cambodia, 
Venezuela 
Dengue Duo, 
Panbio Dengue 
Duo 
and 
Retrospective 
Serum, 
Plasma, and 
Fingerstick 
Whole Blood  
dengue; 
Convalescent 
timepoints: 
15+ days after 
symptom 
onset; All ages 
ELISA Samples 
SD BIOLINE: 
93.9% 
(90.2-96.6%) 
Panbio: 
98% 
(95.5-99.4%) 
Samples 
SD BIOLINE: 
87.1% 
(84.1-89.8%) 
Panbio: 
58.3% 
(54.2-62.4%) 
Sanchez-
Vargas 
2014 
Mexico 
SD BIOLINE 
Dengue Duo 
397 Prospective 
Serum 
Secondary 
infection:  
IgG positive 
regardless of 
NS1 or IgM 
results; 
Negative 
samples from 
other febrile 
IgG Capture 
ELISA 
All Samples: 
 90.1% 
(85.3-94.8%) 
Secondary 
infection: 
83.7% 
(72.3-95.0%) 
 
All Samples: 
92.5%  
(88.8-96.1%) 
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 168 
Abbreviations: ELISA, enzyme-linked immunoassay. ELISPOT-MNT, enzyme-linked immunospot microneutralization test 169 
illnesses 
Pan-Ngum 
2013 
Sri Lanka 
Panbio Dengue 
Duo 
549 Prospective 
Serum 
Suspected 
dengue,  
ages ≥ 16 years 
ELISA All Samples: 
61.9% 
(50.7-72.3%) 
All Samples: 
79.6% 
(75.6-83.1%) 
Moorthy 
2009 
India 
Panbio Dengue 
Duo 
86 Retrospective 
Serum 
Dengue-like 
illness  
IgG Capture 
ELISA 
All Samples: 
87.5% 
All Samples: 
66.6% 
Groen 
2000 
Curacao, 
Indonesia, 
Netherlands 
Panbio Dengue 
Duo 
132 Retrospective 
Serum 
Suspected 
dengue; other 
viral infections 
Consensus 
of multiple 
immunoas-
says 
All samples: 
52% 
All samples: 
100% 
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In total, 3171 samples were tested with RDTs across all the studies. Sample types included 170 
whole blood, plasma, and serum.  No studies examined the performance of dengue RDTs to 171 
detect remote previous infection. Eight of the 10 studies evaluated the ability of the IgG 172 
component of the RDT to detect DENV IgG antibodies present in samples from all suspected or 173 
known dengue patients being evaluated for DENV infection, compared to a laboratory-based IgG 174 
ELISA test. Additionally, four of the 10 studies included samples from individuals described as 175 
having secondary DENV infection (defined in studies as documented previous infection or IgG 176 
positivity) or convalescent timepoints after recent infection (i.e., defined in one study as 15 days 177 
or more after symptom onset), providing some insight into the performance of the IgG 178 
component of the RDTs in individuals who had been infected with DENV previously.  179 
 180 
Figure 2 shows the sensitivity of the dengue RDT IgG component from studies evaluating all 181 
samples from patients with suspected or known DENV infection as well as studies with separate 182 
categories for secondary DENV infection or convalescent timepoints after recent infection.   183 
 184 
Fig 2. Dengue RDT IgG Sensitivity Results   185 
Figure 2 shows the sensitivity estimates and 95% confidence intervals (when reported) for 186 
detection of dengue IgG for each RDT evaluated. Sensitivity in samples from all suspected and 187 
known dengue patients is shown in the top half of the figure, followed by sensitivity in samples 188 
from secondary infections or convalescent timepoints after recent infection in the bottom half.     189 
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 190 
  191 
The most commonly studied RDT was the SD BIOLINE Dengue Duo test, followed by the Panbio 192 
Dengue Duo test, and all RDTs in this review could detect both IgG and IgM. When used in the 193 
context of all samples being tested for DENV infection, the sensitivity of the RDT IgG component 194 
typically ranged between 30-60%. However, when evaluated only in secondary infection or 195 
convalescent timepoint samples, the sensitivity of the RDT IgG component was significantly 196 
higher, typically between 75-98% with wide confidence intervals. This is consistent with the fact 197 
that all samples under evaluation for DENV infection included cases of acute primary infection, 198 
which would have had much lower levels or no IgG antibodies present, depending on when in 199 
the course of infection the samples were drawn.   200 
 201 
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Figure 3 demonstrates the specificity of the dengue RDT IgG component reported across the 202 
studies. In all samples under evaluation for DENV infection, the specificity of the dengue RDTs’ 203 
IgG component ranged from 65-100%, again with wide confidence intervals. When evaluated 204 
only in cases of secondary infection or convalescent timepoints after recent infection, the 205 
specificity rose to between 85-100% in most studies.  206 
 207 
Fig 3. Dengue RDT IgG Specificity Results 208 
Figure 3 shows the specificity estimates and 95% confidence intervals (when reported) for 209 
detection of dengue IgG for each RDT evaluated. Specificity in samples from all suspected and 210 
known dengue patients is shown in the top half of the figure, followed by specificity in samples 211 
from secondary infections or convalescent timepoints after recent infection in the bottom half.     212 
 213 
 214 
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 215 
 216 
Overall, there were no studies that directly evaluated the use of RDTs for determination of 217 
dengue serostatus, as all studies examined RDT performance in the context of either all samples 218 
from patients with possible DENV infection, and/or a subset from samples of secondary 219 
infection or convalescent timepoints after recent DENV infection. Although all studies included 220 
samples from dengue-endemic areas, none of them provided information on vaccination or 221 
infection status of patients for other flaviviruses, all of which may lead to cross-reactivity with 222 
dengue serological testing. Lack of cross-reactivity data is a major limitation for pre-vaccination 223 
screening, since false-positive results due to cross-reactivity to other co-circulating flaviviruses 224 
could lead to inappropriate vaccination of dengue-naïve individuals.  Studies using samples that 225 
have been well-characterized with either ELISA or PRNT for exposure to other flaviviruses, 226 
particularly Zika virus given its genetic similarity to dengue, were absent. Additionally, the 227 
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majority of studies tested serum samples, and not whole blood samples, which are more 228 
relevant for testing at the point-of-care.  There were not enough studies using whole blood to 229 
conclude whether or not the sensitivity and specificity of the test differed compared to serum or 230 
plasma.  231 
 232 
Table 2 summarizes the QUADAS-2 assessment by study, while Table 3 summarizes the GRADE 233 
assessment of the complete body of evidence, using criteria from published guidelines [23,24]. 234 
In the QUADAS-2 assessment, there were high patient selection applicability concerns for all 235 
studies, since none of the RDT tests were exclusively performed on patients with remote 236 
previous DENV infection. This also lead to unclear applicability of the index test, since the 237 
interpretation of an IgG positive result is complicated by the possible detection of IgG in acute 238 
infections and the potential absence of IgG in some cases of previous infection.  239 
 240 
Table 2. QUADAS-2 Assessment of Studies 241 
 Risk of Bias Applicability Concerns 
Study Patient 
Selection 
Index 
Test 
Reference 
Standard 
Flow & 
Timing 
Patient 
Selection 
Index 
Test 
Reference 
Standard 
Vickers 2017  Low Low Low Low High Unclear Low 
Piedrahita 2016 Low  Low Low Low High Unclear Low 
Vickers 2015 Low Low Low Low High Unclear Low 
Krishnananthasivam 
2015 
Low Low Low Low High Unclear Low 
Lee 2015 Unclear Low Low Low High Unclear Low 
Pal 2015 Low Low Low Low High Unclear Low 
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Sanchez-Vargas 
2014 
Low Low Low Low High Unclear Low 
Pan-Ngum 2013 Low Low Low Low High Unclear Low 
Moorthy 2009 Low Low Low Low High Unclear Low 
Groen 2000 Low Low Unclear Low High Unclear Unclear 
 242 
In the GRADE assessment, the overall certainty of evidence for using dengue DTs for 243 
determination of dengue serostatus was low. The indirectness of evidence was serious given the 244 
fact that no study evaluated the RDTs for the detection of remote previous DENV infection only. 245 
Additionally, the inconsistency of the studies was serious, as studies varied in how they defined 246 
secondary infection, the population studied, the laboratory reference standard used, the cutoffs 247 
used to define a positive and negative IgG result, and how samples were chosen for inclusion in 248 
the evaluations. Due to these differences across studies, a meta-analysis of data was not 249 
conducted. Further data analysis and subpopulation analyses were not done due to the absence 250 
of data relating to vaccination status, age groups, other flaviviruses, and time since infection, as 251 
well as the overall heterogeneity of study designs.  252 
 253 
 254 
Table 3. GRADE Evaluation of Evidence Quality 255 
Number 
of 
Studies 
Study 
Design 
Risk of 
bias 
Inconsistency Indirectness Imprecision Quality Importance 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 20
10 Cohort 
Studies 
Not 
Serious 
Serious Serious Not Serious Low Critical 
 256 
 257 
Semi-structured interviews were conducted with dengue rapid test product managers from 4 258 
dengue RDT manufacturers (Abbott/Alere, Bio-Rad, CTK Biotech, and GenBody) who responded 259 
to an interview request, along with Sanofi-Pasteur, the manufacturer of Dengvaxia®. 260 
Manufacturers noted that dengue RDTs have typically been designed to detect the higher levels 261 
of IgG that can be present soon after primary and secondary DENV infections and not low-level 262 
IgG, though the specific limit of detection for IgG for each test is not publicly available. 263 
Furthermore, current RDTs do not have regulatory approval and were not validated for 264 
determination of dengue serostatus. An RDT optimized to detect remote prior infection would 265 
benefit from having higher sensitivity for IgG than current RDTs, as IgG levels can wane over the 266 
course of time; however, additional testing would be needed to ensure that this does not result 267 
in increased cross-reactivity with other flaviviruses.  Manufacturers also indicated that this 268 
should be technically feasible, given the research already done to develop current RDTs as well 269 
as the technical expertise from using and developing laboratory-based ELISA tests, which 270 
typically have higher IgG sensitivity. Additional discussions over whether total DENV IgG or IgG 271 
specific to particular DENV antigens would be helpful, as well as whether other analytes (e.g., 272 
IgM or other analytes found in current tests) are needed would also be helpful to guide the final 273 
design of an RDT. 274 
 275 
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Discussion 276 
In acute secondary DENV infections and convalescent timepoints after recent infection, the 277 
sensitivity and specificity of the IgG component of dengue RDTs was typically above 75% and 278 
80%, respectively, when compared to IgG detection by laboratory-based ELISA testing.  279 
However, a major limitation is the fact that no study evaluated the performance of RDTs for past 280 
DENV infection, as studies only used early convalescent samples or samples from presumed 281 
acute primary or secondary infection. Therefore, no data are available on RDTs that have tested 282 
IgG for DENV infections in the remote past.  283 
 284 
Studies varied depending on the population studied, the types of samples included in each 285 
study, how secondary infections were determined, what cutoffs were used to categorized IgG 286 
levels as positive or negative, and the reference standard test used.  Sensitivity and specificity of 287 
the IgG component were lower when the dengue samples tested included acute primary 288 
infection samples. This may be due to the lack of IgG or low-levels of IgG present in samples 289 
taken soon after infection, where IgM constitutes the primary initial immune response.  290 
 291 
This systematic review did not identify any studies that specifically evaluated dengue RDTs for 292 
determining dengue serostatus in the context of remote prior infection only. The review also 293 
identified four major challenges of use of dengue RDTs for detecting prior infection: 294 
1) Data challenges  295 
The studies included in this review evaluated the performance of the IgG component of 296 
dengue RDTs in the following groups: 1) all samples from individuals with suspected 297 
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DENV infection and/or 2) samples from individuals described as having secondary DENV 298 
infection or convalescent timepoints after recent infection. Although these groups are 299 
not equivalent to individuals with more remote previous DENV infection, they do provide 300 
some insight into the performance of dengue RDTs for identifying IgG antibodies as 301 
compared to a laboratory-based test. However, their performance in these populations 302 
should be taken as an overestimate compared to an overall population presenting for 303 
vaccination screening, since the groups studied typically have higher IgG levels that are 304 
much easier to detect compared to a general population. This will primarily impact the 305 
sensitivity of the assays. The extent of specificity will vary depending on the population 306 
from which dengue-negative reference samples were drawn (e.g., this ranges from using 307 
US adults as dengue-negative controls to samples from dengue-endemic populations). 308 
 309 
2) Regulatory challenges 310 
Determination of dengue serostatus is not explicitly included as an approved part of the 311 
intended use statements of dengue RDTs. This is not surprising, given the fact that the 312 
primary intention for these RDTs has been the diagnosis of acute DENV infection in 313 
patients with febrile illness.  However, the label and intended use for some of these 314 
tests, where it is described as an aid to “diagnosis of DENV infection” may be interpreted 315 
to include determination of past infection.  As an example, the SD Bioline Dengue Duo 316 
intended use is to “aid in the presumptive diagnosis between primary and secondary 317 
dengue infection.” However, IgG can still be detected during and shortly after acute 318 
primary infection, which can complicate the distinction between primary and secondary 319 
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infection. Regulatory authorities may interpret use of RDTs for determination of past 320 
DENV infection as off-label usage, which may lead to procurement and implementation 321 
challenges, depending on local policies. Additional research on the use of RDTs for 322 
measuring past infection would benefit from following local and regional regulatory 323 
requirements, in order to assist RDTs in obtaining an indication for this use.  324 
 325 
3) Technical challenges 326 
Since IgG antibody levels can be higher during or soon after acute infection, RDTs that 327 
have been optimized to diagnose acute infection may not be suitable for detection of 328 
lower IgG antibody levels in individuals with more remote prior DENV infection. This may 329 
help to explain the lower sensitivity of the IgG component seen in some studies, 330 
although the limit of detection for IgG for each test is not publicly available information.  331 
Additionally, dengue serological tests can cross-react with antibodies to other 332 
flaviviruses, such as West Nile virus and Zika virus, and none of the studies in this review 333 
characterized the occurrence of other flaviviruses in their sample sets. Lowering the titer 334 
of IgG antibodies that RDTs can detect in order to increase sensitivity for detection of 335 
past infection may also lead to lower specificity. More specific antigens could also be 336 
explored. Furthermore, specificity may vary depending on the prevalence of other 337 
flavivirus infections as well as vaccinations used for other flaviviruses. Therefore, the 338 
relatively high sensitivity and specificity of RDTs may show that they match up well with 339 
commercial ELISAs designed to diagnose acute infection only. Additional research would 340 
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be helpful to compare RDTs not only to ELISAs, but also to PRNT assays, which may be a 341 
more specific measure of DENV exposure and may be a superior reference standard.  342 
 343 
4) Impact of Zika virus  344 
Most of the evaluations were conducted before the emergence of Zika virus, which is 345 
highly related to DENV. However, recent research on antibody cross-neutralization 346 
suggests that ZIKV lies outside the dengue virus serocomplex [35]. In a study on 347 
longitudinal serologic specimens from Latin America and Asia, ZIKV neutralizing antibody 348 
titers in patients after ZIKV showed low-level cross-reactivity to DENV that was greater in 349 
dengue-immune individuals [35]. These antibodies may be able to distinguish ZIKV from 350 
DENV infections, although additional research is needed to determine this. Over time it 351 
may become harder to distinguish the two viruses, and more specific antigens or tests 352 
may be necessary.  353 
 354 
Strengths of this systematic review included over 3000 DENV samples tested,  including a 355 
smaller subset of secondary infections and convalescent timepoints after recent infection, the 356 
geographic diversity of studies, and the inclusion of a number of different commercially-357 
available dengue RDTs and sample types. However, the review was limited by the heterogeneity 358 
of data and the inability to evaluate factors such as infection with other flaviviruses and the 359 
potential impact of other flavivirus vaccines.  360 
 361 
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With such a paucity of data on the use of dengue RDTs for determining serostatus, further 362 
research is necessary to inform pre-vaccination screening approaches for dengue, as it is 363 
currently difficult to draw distinct conclusions regarding the performance of RDTs for this use.  364 
Studies could examine the performance of current RDTs for the direct purpose of determining 365 
serostatus, investigate the performance of the test in areas with co-circulating flaviviruses and 366 
vaccination, and assess the use of other reference standards such as PRNT. Based on the 367 
performance of currently available dengue RDTs in secondary infection and convalescent 368 
timepoints after recent infection, the IgG component of these RDTs do have reasonable 369 
performance for detection of these infections compared to conventional laboratory-based ELISA 370 
testing.  However, further discussion within the scientific and public health community is 371 
needed to determine if this performance is sufficient for pre-vaccination screening or not. The 372 
decision to use RDTs will likely also depend on local factors, such as dengue seroprevalence, the 373 
availability of alternative tests, and the public health risk and benefit from vaccination.  374 
 375 
Development of new dengue RDTs or modification of currently available RDTs may be the most 376 
beneficial for vaccination screening. Tests with higher sensitivity and specificity, and even new 377 
antigen or antibody targets can be investigated and validated by dengue RDT manufacturers, 378 
who have the necessary expertise to provide regulatory approved tests suitable for pre-379 
vaccination screening [35].  Alternatively, in settings with sufficient laboratory capacity, 380 
laboratory-based testing may also considered, although slower turnaround time of these tests 381 
may lead to high rates of individuals not returning for their test results or vaccination [36]. 382 
Vaccination programs should evaluate all currently available testing options to determine how 383 
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best to evaluate for dengue serostatus in order to ensure safe and effective vaccination.  New 384 
tests may be needed with high sensitivity and specificity at the point-of-care to avoid excluding 385 
individuals who would benefit from vaccination while at the same time preventing the inclusion 386 
of individuals who should not be vaccinated.   387 
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